Cipla Limited has announced the commercialisation of a polymerase chain reaction (RT-PCR) test kit ViraGen for COVID-19 in India, in partnership with Ubio Biotechnology Systems Pvt. Ltd. 

ViraGen is Cipla’s third offering in the Covid-19 testing segment. Cipla already has partnerships for antibody detection kits and antigen test kits. ViraGen is a real-time detection kit approved by the ICMR (Indian Council of Medical Research) and is based on multiplex PCR technology. It helps to identify and detect SARS CoV-2 N Gene and ORF Lab Gene with the sensitivity of 98.6% and the specificity of 98.8% as compared to a standard ICMR test. 

This test is designed for the qualitative detection of nucleic acid from SARS-CoV-2 in the upper and lower respiratory specimens from individuals suspected of COVID-19. 

ViraGen used for qualitative detection of SARS-CoV-2 will be manufactured by Ubio Biotechnology Systems and marketed and distributed by Cipla through its expansive distribution network across the country. 

This launch will help address the current testing services and capacity issues while reaffirming the company’s ongoing expansion in the diagnostic space. The company commence supply of the detection kit from May 25, 2021. 

Commenting on the partnership, Umang Vohra, MD & Global CEO, Cipla said, “Cipla has been working relentlessly to ensure accessibility to treatments in this fight against COVID-19. Guided by our core purpose of ‘Caring for Life’, this partnership will enable us to reach out to more people across the country at a crucial time like now.”